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Abstract
Background: Preclinical studies strongly suggest that accelerated apoptosis in skeletal myocytes may be involved in the
pathogenesis of sarcopenia. However, evidence in humans is sparse. In the present study, we investigated whether
apoptotic signaling in the skeletal muscle was associated with indices of muscle mass and function in older persons.
Methodology/Principal Findings: Community-dwelling older adults were categorized into high-functioning (HF) or low-
functioning (LF) groups according to their short physical performance battery (SPPB) summary score. Participants
underwent an isokinetic knee extensor strength test and 3-dimensional magnetic resonance imaging of the thigh. Vastus
lateralis muscle samples were obtained by percutaneous needle biopsy and assayed for the expression of a set of apoptotic
signaling proteins. Age, sex, number of comorbid conditions and medications as well as knee extensor strength were not
different between groups. HF participants displayed greater thigh muscle volume compared with LF persons. Multivariate
partial least squares (PLS) regressions showed significant correlations between caspase-dependent apoptotic signaling
proteins and the muscular percentage of thigh volume (R
2=0.78; Q
2=0.61) as well as gait speed (R
2=0.81; Q
2=0.56).
Significant variables in the PLS model of percent muscle volume were active caspase-8, cleaved caspase-3, cytosolic
cytochrome c and mitochondrial Bak. The regression model of gait speed was mainly described by cleaved caspase-3 and
mitochondrial Bax and Bak. PLS predictive apoptotic variables did not differ between functional groups. No correlation was
determined between apoptotic signaling proteins and muscle strength or quality (strength per unit volume).
Conclusions/Significance: Data from this exploratory study show for the first time that apoptotic signaling is correlated
with indices of muscle mass and function in a cohort of community-dwelling older persons. Future larger-scale studies are
needed to corroborate these preliminary findings and determine if down-regulation of apoptotic signaling in skeletal
myocytes will provide improvements in the muscle mass and functional status of older persons.
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Introduction
Over the past decades, the 75+ years age group has been the
most rapidly expanding segment of the population in Western
countries [1]. Unfortunately, this group is also the most susceptible
to developing functional impairments and disability [2]. Indeed,
the increase in life expectancy has not been paralleled by a
proportional expansion in disability-free lifespan [3]. As a result,
although several indices of functional limitations have shown
improvements in the last two decades, over 20% of older
American adults are presently disabled [3].
Sarcopenia, the age-related involuntary decline in skeletal
muscle mass and function, is a major determinant of frailty and
disability [4]. Furthermore, decreased muscle mass and strength
are independently associated with mortality in older persons [5,6].
The biological determinants of muscle aging remain elusive;
however, several lines of evidence suggest that acceleration of
apoptosis in skeletal myocytes during aging may represent a
converging mechanism through which sarcopenia and physical
function decline ensue (reviewed in [7]). Noteworthy, chronic low-
grade inflammation and oxidative stress secondary to mitochon-
drial dysfunction, two processes believed to contribute to muscle
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e32829aging [8], are powerful inducers of skeletal myocyte apoptosis
[9,10]. Moreover, down-regulation of apoptotic signaling in
myocytes via pharmacological [11–14] and behavioral interven-
tions [10,15–19] or genetic manipulations [20] has been associated
with attenuation of muscle loss and physical function decline in
aged experimental animals. Conversely, up-regulation of apoptotic
signaling secondary to the accumulation of critical levels of
mitochondrial DNA (mtDNA) mutations, results in a premature
aging phenotype and severe sarcopenia in mice expressing a
proofreading deficient mtDNA polymerase [21]. Similarly, mice
lacking the antioxidant enzyme copper/zinc-dependent superox-
ide dismutase (CuZnSOD or Sod1) develop marked sarcopenia
accompanied by skeletal myocyte morphological and biochemical
abnormalities, including enhanced apoptosis [22]. Remarkably,
the genetic characterization of interleukin 10-deficient mice, a
rodent model of frailty, unveiled up-regulation of several skeletal
muscle apoptosis-related genes [23], further supporting the
involvement of accelerated myocyte apoptosis in the pathogenesis
of sarcopenia and physical frailty in late life.
Although studies in experimental animal models implicate
apoptosis as a mechanism in muscle aging, evidence in humans is
still lacking. To date, only three reports have been published
examining the occurrence of skeletal myocyte apoptosis in older
persons [24–26]. However, only one of these studies was
performed on muscle specimens from living human subjects [26]
and none investigated either specific biochemical pathways of
apoptosis or the relationship between apoptotic signaling and
measures of physical performance. Hence, the present exploratory
study was designed to investigate whether the extent of apoptosis
activation and signaling through specific apoptotic pathways were
linked with functional status in older persons. The main hypothesis
underlying this study was that older individuals with poor physical
function would display reduced muscle mass and strength
concomitant with enhanced apoptotic signaling relative to their
high-functioning peers.
Materials and Methods
Ethics Statement
Prior to enrollment in the study, all participants provided
written informed consent. In no case informed consent was
obtained from next of kin, carers or guardians on the behalf of
participants. The study was approved by the University of
Florida’s Institutional Review Board.
Objectives
The aim of the study was to explore the relationship between
the extent of apoptosis activation in the skeletal muscle and
measures of muscle mass and physical performance in older
persons. The relationship between signaling through specific
apoptotic pathways and indices of muscle mass and function was
also investigated.
Participants
Participants were community-dwelling men and women aged
70 years or older, categorized in high-functioning (HF) or low-
functioning (LF) based on their short physical performance battery
(SPPB) summary score [27]. Specifically, persons with a
performance score $11 were assigned to the HF group, whereas
those with a summary score #7 were considered LF. These cutoff
limits were selected based on their ability to predict several
relevant health outcomes in older adults, including functional
limitations, institutionalization and mortality [28–30]. Persons
scoring 8–10 at the SPPB were excluded to allow a greater
distinction in physical function and possibly muscle biochemical
parameters between groups. Additional exclusion criteria were:
smoking in prior 12 months; history of drug or alcohol abuse;
engagement in regular physical exercise; active treatment for
cancer or cancer in the past three years; heart failure New York
Heart Association (NYHA) class III–IV; stroke with upper and/or
lower extremity involvement; Parkinson’s disease or other
neurological disorders likely to interfere with physical function;
major psychiatric illnesses; peripheral vascular disease Le ´riche-
Fontaine stage 3–4; history of life-threatening cardiac arrhythmias;
cognitive impairment (i.e., MiniMental State Examination score
#21); renal disease requiring dialysis; lung disease requiring
steroids; chronic viral diseases (e.g., hepatitis B and C, HIV); lower
extremity amputation; severe knee or hip osteoarthritis limiting
mobility; diabetes with visual, vascular or neuropathic complica-
tions; inflammatory diseases (e.g., rheumatoid arthritis, vasculitis,
autoimmune disorders and inflammatory bowel disease); taking
growth hormone, estrogen replacement, testosterone, anticoagu-
lants, steroids, non-steroidal anti-inflammatory drugs on a regular
basis; severe obesity [i.e., body mass index (BMI)$35]; under-
weight (i.e., BMI#18.5); active weight loss .5 kg in prior three
months; lidocaine allergy; life-threatening illnesses with an
estimated life expectancy ,1 year. Temporary exclusion criteria
were: recent bacterial/viral infection (,2 weeks); acute febrile
illness in prior two months; high blood pressure (i.e., $180/
110 mm Hg) at the screening visit; major surgery or hip/knee
replacement in the past six months; statin treatment (subjects were
asked to refrain from statin administration one month prior to the
muscle biopsy upon their general practitioner’s approval); other
acute diseases interfering with mobility as indicated by the
participant’s general practitioner. Eligible persons were excluded
if they had contraindications to the execution of magnetic
resonance imaging (MRI), including claustrophobia, heart pace-
maker/defibrillator, metallic stents, aneurysm clips, metal implants
or prosthesis, neurostimulation systems, insulin pumps or other
infusion pumps.
Screening and recruitment procedures
Recruitment of participants was coordinated by the Recruit-
ment Core of the University of Florida Claude D. Pepper Older
Americans Independence Center. Recruitment strategies included
media articles, direct mailings, newspaper announcements, and
presentations to community groups. Following telephone screen-
ing, eligible persons were invited to attend a screening visit during
which the purpose and procedures of the study were explained and
informed consent was obtained. After the participant provided
consent, a general assessment was completed to determine his/her
standing height, body mass, BMI, and blood pressure.
Description of Procedures and Investigations undertaken
Physical function assessment. To assess physical function,
the SPPB and knee extensor strength were determined. The SPPB
is composed of three subtasks: usual gait speed (GS), standing
balance and chair-stand tests [27]. GS was evaluated over a 4-
meter course at the person’s usual pace. The faster of two trials
(m/s) was used for the analysis. For the standing balance test,
participants were asked to stand in three progressively more
difficult positions for 10 s each: a side-by-side feet standing
position, a semi-tandem position and a full-tandem position. For
the chair-stand test, participants were asked to perform five
repetitions of standing up and sitting down from a chair without
using hands and the performance was timed. Each of the three
SPPB subtasks was categorized into a 5-level score, with zero
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highest level of performance.
Knee extension strength was determined using a Biodex
dynamometer (Biodex Medical System, Shirley, NY) to measure
the maximal concentric isokinetic strength of knee extensors of the
dominant leg. Participants were asked to exert their maximum
force while extending the knee from 90u to 0u of flexion at 60u per
second with a hip angle of 90–100u. Two practice repetitions were
completed prior to three test repetitions. The maximal peak torque
achieved was used for the analysis both as the absolute value (N?m)
and the ratio between peak torque and BMI.
MRI for the quantification of thigh muscle volume. T1-
weighted MRI was employed to quantify the thigh muscle volume
(MV) of the dominant leg. Images were obtained using a 3.0-tesla
magnet (Philips Medical Systems, Bothell, WA), as detailed
elsewhere [31]. Briefly, three-dimensional data were collected
using a body coil and a fast gradient-echo sequence, with
repetition time (TR)=100 ms, time to echo (TE)=10 ms, flip
angle=30u, and chemically-selective fat suppression. Images were
acquired with an encoding matrix of 2566256, a field of view of
16–24 cm and 7-mm slice thickness. For image analysis, the
maximal cross-sectional area of the biceps femoris was identified.
Subsequently, volumetric analysis was performed on 11
contiguous axial slices (10-mm thickness), five proximal and five
distal from that corresponding to the maximal thigh cross-sectional
area. Muscle tissue was quantified volumetrically, with results
reported as the absolute volume (cm
3) and percentage of the total
thigh volume (hereby referred to as percent MV). The ratio
between MV and BMI was also calculated.
Images were analyzed using the freely-available software
package MIPAV 1.3 (Medical Image Processing, Analysis and
Visualization; Center for Information Technology, National
Institutes of Health, Bethesda, MD; http://mipav.cit.nih.gov).
MRI data were also used for muscle quality determination, which
was calculated as the ratio between maximal peak torque and
thigh MV (N?m/cm
3).
Muscle biopsy. Muscle samples were obtained from the
vastus lateralis of the dominant leg by percutaneous needle biopsy,
under local anesthesia [32]. Muscle specimens were cleaned of any
visible blood and fat, frozen in liquid nitrogen and stored at
280uC until analysis.
Subcellular fractionation and immunoblotting. Isolation
of cytosolic, mitochondrial and nuclear fractions from muscle
samples was performed as previously described [9]. Electrophoresis
and immunoblotting were carried out as detailed elsewhere [10].
Cytosolic fractions were used to assess the protein expression of
cleaved caspase-3 (Millipore, Temecula, CA), active caspase-8
(Abcam, Cambridge, MA), tumor necrosis factor receptor 1 (TNF-
R1; Abcam) and cytochrome c (Santa Cruz Biotechnology, Santa
Cruz, CA). Expression levels of Bcl-2, Bax and Bak (all from Santa
Cruz Biotechnology) were assayed in mitochondrial fractions.
Finally, endonuclease G (EndoG; Abcam) and apoptosis-inducing
factor (AIF; BD Biosciences, San Jose, CA) protein levels were
assessed in mitochondrial and nuclear fractions. Digitalimageswere
captured with an Alpha Innotech Fluorchem SP imager (Alpha
Innotech, San Leandro, CA) and analyzed using the built-in
software as previously described [10].
Statistical methods
Continuous descriptive variables were analyzed by the Mann-
Whitney U test, whereas the x
2 test was used for categorical
variables. To explore correlations between apoptotic signaling
proteins and functional measures (i.e., GS, knee extensor strength
and thigh muscle quality) or MRI data (percent MV), multivariate
regressions were performed via partial least squares (PLS) analyses.
Briefly, the idea beneath multivariate analysis methods, such as the
PLS, is that each subject is represented by a single data point in a
multidimensional space where each measured variable is one of
the coordinate axes. The goal of multivariate PLS regressions is
the reorientation of data points along new axes, that are
algebraically expressed by a linear combination of the original
variables, to guide the projections into meaningful directions by
using an external (‘‘response’’) variable. The new axes are
commonly referred to as ‘‘components’’ or ‘‘factors’’.
PLS was performed on a data matrix where each subject was
represented by a row, with each apoptosis-related variable
corresponding to a column. Functional measures or imaging data
were added as the variables against which multivariate regressions
were run. Matrices were pre-processed by mean-centering and
scaling (i.e., means of each column were set to zero and their
standard deviations were set to one) [33]. This procedure is
commonly applied to data matrices prior to PLS because it allows
the comparison of covariations of variables independent of their
numerical size, while maintaining their factorial structures [33].
PLS was validated by full cross-validation. According to this
procedure, the same samples are used for both model estimation
and testing. In each cross-validation step, one sample is left out
from the calibration data set and the model is calibrated on the
remaining data points. Values for the left-out samples are
predicted, and prediction residuals are computed. The process is
repeated with all other subsets of the calibration set until every
object has been left out once. All prediction residuals are finally
combined to compute the validation residual variance, commonly
reported as ‘‘validation R
2’’ or Q
2. In addition, in order to assess
the stability of validated models, the Marten’s uncertainty test was
applied, which couples the full cross-validation to the jackknife
principle [34]. For every cross-validation sub-model, a set of model
parameters (i.e., B-coefficients, scores, loadings and loading
weights) were calculated, and variations over these sub-models
estimated to assess the stability of results. The number of
components on which PLS regression models were built was
selected by the statistical software on the basis of the cross-
validation test.
Separate PLS models were constructed for caspase-dependent
(TNF-R1, active caspase-8, cleaved caspase-3, cytosolic cyto-
chrome c) and caspase-independent apoptotic signaling proteins
(mitochondrial and nuclear AIF, mitochondrial and nuclear
EndoG), with mitochondrial Bcl-2, Bax and Bak included in both
models. Apoptotic variables identified as significant by the
uncertainty test were examined via Mann-Whitney U tests to
determine differences between HF and LF subjects. The same test
was used to compare PLS predictive apoptotic proteins between
participants with percent MV or GS above and below the median
value of the study sample. All tests were two-sided with significance
set at p,0.05. All data are presented as mean 6 standard
deviation (SD).
PLS analyses were performed using the Unscrambler X 10.1
software (CAMO Software, Oslo, Norway), whereas the Graph-
Pad Prism 4.0.3 software (GraphPad Software, San Diego, CA)
was used for Mann-Whitney and x
2 tests.
Results
Descriptive characteristics of the study sample
A total of 43 community-dwelling older adults (25 HF and 18
LF) were recruited. Muscle biopsies yielded sufficient tissue to
perform all biochemical analyses in 13 HF and 7 LF persons.
Demographic, functional and imaging parameters as well as the
Apoptosis, Sarcopenia and Physical Function
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participants were consistent with the rest of the study sample,
except for containing a higher proportion of males (75% vs. 35%;
p,0.05). The main characteristics of participants with complete
muscle biochemistry data are shown in Table 1. The two
functional groups did not differ with respect to age, sex
distribution, ethnicity, BMI or number of disease conditions and
medications. Compared with LF persons, HF participants
performed significantly better at the walking test and the chair-
stand test of the SPPB [27]. In particular, the 4-meter walking
speed, a functional parameter predictive of several relevant
outcomes in older persons [35], was lower in the LF group
relative to HF persons. No significant difference was determined
between groups for the balance test score. However, HF
participants displayed greater MV compared with the LF group.
Finally, neither knee extensor strength nor thigh muscle quality
(strength per unit volume) differed significantly between HF and
LF persons.
Multivariate PLS regressions of skeletal muscle apoptotic
signaling proteins vs. imaging and functional data
The regression of caspase-dependent apoptotic signaling
proteins versus percent MV yielded a regression model based on
four components, explaining 78.3% of the overall Y variance, with
a cross-validation Q
2 of 0.61 (Figure 1A). The uncertainty test
revealed that four of the original variables were mainly involved in
the description of the model, namely active caspase-8, cleaved
caspase-3 and cytosolic cytochrome c (inverse correlation), and
mitochondrial Bak (direct correlation) (Figure 1B). No correlation
was determined between caspase-independent signaling proteins
and percent MV (data not shown). Moreover, neither caspase-
dependent nor caspase-independent apoptotic signaling proteins
were correlated with knee extensor strength or thigh muscle
quality (data not shown). A 4-component model was obtained
from the regression of caspase-dependent apoptotic signaling
proteins versus GS. The model explained 81.3% of the overall Y
variance, with a cross-validation Q
2 of 0.56 (Figure 2A). Variables
involved in the description of this PLS model were cleaved
caspase-3 and Bax (inverse correlation), and Bak (direct correla-
tion) (Figure 2B). Caspase-independent apoptotic signaling pro-
teins were not correlated with GS (data not shown).
Comparisons of PLS predictive apoptotic variables between HF
and LF participants via Mann-Whitney U tests revealed no
significant differences (Table 2). However, protein levels of active
caspase-8 and cytosolic cytochrome c were higher in persons with
percent MV below the median value of the study sample (48.6%;
LF=6, HF=4; Figure 3). Conversely, levels of apoptotic proteins
predictive of GS were not significantly different in participants
walking faster than the median speed of the study population
(1.01 m/sec; LF=0, HF=10) compared with slower walkers
(LF=7, HF=3; data not shown).
In summary, multivariate PLS regression analyses identified
significant correlations between caspase-dependent apoptotic
signaling proteins and percent MV as well as GS, in the absence
of clear differences in individual apoptotic signaling proteins
between the two functional groups.
Table 1. Characteristics of study participants with complete muscle biochemistry data according to the level of physical
performance (high vs. low).
HF (n=13)
n (%) or mean ± SD
LF (n=7)
n (%) or mean ± SD p value
Age (years) 77.366.4 81.464.2 0.1651
Sex (female) 2 (15) 3 (43) 0.4169
Ethnicity
- Caucasian 12 (92) 6 (86) 0.9012
- Afro-American 0 (0) 1 (14)
- Other 1 (8) 0 (0)
BMI (kg/m
2)2 7 . 2 63.6 27.663.8 0.8121
Number of comorbid conditions* 0.660.8 1.361.0 0.1075
Number of medications 2.261.4 2.461.5 0.6373
SPPB summary score 11.560.5 5.461.9 0.0004
- Balance test subscore 4.060.0 2.661.8 0.0545
- Chair-stand test subscore 3.560.5 0.660.8 0.0004
- 4-meter walking test subscore 4.060.0 2.360.5 0.0004
4-meter walking speed (m/s) 1.1660.21 0.6460.13 0.0006
Knee extensor strength
- Absolute (N?m) 117.9631.2 87.3632.1 0.1131
- BMI-adjusted 4.3461.25 3.2061.21 0.0573
Thigh muscle volume
- Absolute (cm
3) 473.46110.0 330.4655.1 0.0044
- % of total thigh volume 52.468.5 37.268.2 0.0044
- BMI-adjusted 17.663.8 12.162.2 0.0056
Thigh muscle quality (N?m/cm
3) 0.2560.06 0.2760.09 0.6920
*includes hypertension, coronary artery disease, prior stroke, peripheral vascular disease, diabetes, chronic obstructive pulmonary disease, and osteoarthritis.
doi:10.1371/journal.pone.0032829.t001
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Preclinical studies have implicated apoptosis in skeletal myocytes
as a mechanism contributing to sarcopenia. Whether apoptotic
signaling is associated with muscle mass and function in older adults
has yet to be established. Here, we investigated the relationship
between apoptotic signaling and measures of muscle mass and
physical performance in a cohort of relatively healthy, community-
dwelling older persons. Our analyses indicate that signaling proteins
pertaining to caspase-dependent apoptotic pathways are predictive
of percent MV and GS. Conversely, no significant correlations were
determined between caspase-independent apoptotic signaling
proteins and imaging or functional measures. Finally, none of the
apoptotic pathways investigated was correlated with either knee
extensor strength or thigh muscle quality. Noteworthy, our results
indicate that caspase-dependent apoptotic signaling proteins are
predictive of two parameters (i.e., percent MV and GS) that have
recently been proposed by the European Working Group on
Sarcopenia in Older People (EWGSOP) for the screening and
diagnosis of sarcopenia in clinical settings [4].
The loss of muscle mass and function with advancing age is a
major determinant of frailty, disability and mortality [4]. Hence,
the identification of biological pathways underlying muscle aging is
of utmost importance for designing targeted interventions against a
major health issue in the elderly. Accumulating preclinical
evidence suggests that an acceleration of apoptosis in skeletal
myocytes occurs over the course of aging, likely contributing to the
pathogenesis of sarcopenia (reviewed in [7]). Findings from the
present study are consistent with these observations and
demonstrate for the first time that apoptotic signaling is correlated
with a measure of muscle mass in older persons. In keeping with
our previous studies in laboratory rodents [9,10,18], our findings
also suggest that signaling proteins of the death-receptor and
mitochondria-mediated apoptotic pathways may be involved in
Figure 1. Multivariate PLS regression of caspase-dependent apoptotic signaling proteins versus percent muscle volume. (a) The
regression yielded a 4-component model explaining 78.3% of the overall Y variance (Q
2=0.61). Black triangles correspond to low-functioning
participants; grey squares represent high-functioning subjects. (b) Regression coefficients of apoptotic signaling proteins according to the Marten’s
uncertainty test. Significant variables are represented by grey bars. Error bars indicate uncertainty limits.
doi:10.1371/journal.pone.0032829.g001
Figure 2. Multivariate PLS regression of caspase-dependent apoptotic signaling proteins versus gait speed. (a) The regression yielded
a 4-component model explaining 81.3% of the overall Y variance (Q
2=0.56). Black triangles correspond to low-functioning participants; grey squares
represent high-functioning subjects. (b) Regression coefficients of apoptotic signaling proteins according to the Marten’s uncertainty test. Significant
variables are represented by grey bars. Error bars indicate uncertainty limits.
doi:10.1371/journal.pone.0032829.g002
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becomes engaged in the apoptotic signaling following binding of
TNF-a to its cell surface receptor, and subsequently activates
effector caspases, such as caspase-3 (death-receptor apoptotic
pathway) [36]. Furthermore, through the cleavage of pro-
apoptotic Bid, caspase-8 represents a point of convergence
between TNF-a signaling, mitochondria-driven apoptosis and
mitochondrial dysfunction [37]. Hence, our data may provide a
further explanation to previous reports showing that elevated
circulating TNF-a levels are associated with reduced muscle mass
in advanced age (reviewed in [38]). Moreover, our results are
consistent with the involvement of mitochondrial apoptotic
signaling in muscle loss in old age. Indeed, mitochondrial Bak
and cytosolic cytochrome c were among the variables mainly
involved in the description of the regression between apoptotic
signaling and percent MV (Figure 1B). It is interesting to note that,
while cytosolic cytochrome c levels were inversely correlated with
percent MV, which is consistent with the pro-apoptotic activity of
this molecule upon its release from mitochondria, a direct
correlation was determined for Bak. According to the current
understanding, Bak, in association with other apoptogenic proteins
(e.g., Bax), forms of a pore in the outer mitochondrial membrane,
through which apoptotic factors such as cytochrome c can be
released from the mitochondrial intermembrane compartment
into the cytoplasm [39]. One possible explanation to the
discrepancy between our findings and the pro-apoptotic role
traditionally attributed to Bak arises from the demonstration of the
existence of an anti-apoptotic Bak isoform (N-Bak) generated
through alternative splicing [40]. Although N-Bak appears to be
neuron-specific, the possibility that a similar anti-apoptotic Bak
variant might also be expressed in the skeletal muscle warrants
further investigation.
Several mechanisms may be invoked to explain the relationship
between myocyte apoptosis and muscle loss. In multinucleated
skeletal myofibers, the execution of apoptosis results in the
elimination of individual myonuclei (myonuclear apoptosis) and
a corresponding portion of the sarcoplasm. Over time, this
process, coupled with insufficient satellite cell replenishment, may
eventually lead to fiber atrophy [41]. Furthermore, apoptotic
signaling may induce the degradation of contractile proteins,
resulting in decreased myofiber cross-sectional area without
myonuclear removal or fiber death [42]. In fact, caspase-3 is
required for initiating the proteolytic degradation of actinomyosin
complexes and myofibrils by generating monomeric actin and
actin fragments which are subsequently degraded by the
proteasome [43].
Another major finding of the study is that apoptotic signaling in
the skeletal muscle is predictive of walking speed. In recent years,
GS at usual pace has been increasingly recognized as a powerful
predictor of adverse health outcomes in older persons, including
disability, hospitalization, institutionalization and mortality
[28,30,44]. As such, GS is being advocated as an additional vital
sign in older adults, due to its potential to distinguish chronological
from biological age [35]. Although walking speed is dependent on
multiple organ systems (e.g., cardiovascular, respiratory and
nervous systems), it is undoubted that muscle function is central
in determining how fast an individual can walk. From this
perspective, the correlation between apoptotic signaling proteins
and GS observed in our study is especially intriguing, as it suggests
that this cellular pathway may be involved in the disabling process.
The mechanisms whereby apoptosis may impact GS are
multifaceted. As previously discussed with regard to muscle
atrophy, apoptotic signaling in skeletal myocytes may result in
the degradation of contractile elements, followed by reduced
muscle mass and force generation with or without myonuclear
elimination. In addition, apoptotic signaling may be accompanied
by mitochondrial bioenergetic failure and increased generation of
reactive oxygen species (ROS), resulting in ATP depletion and
oxidative damage to cellular macromolecules [45]. This hypothesis
is supported by the observation that impaired mitochondrial
Table 2. Expression levels of PLS predictive apoptotic
signaling proteins in the two functional groups.
HF (n=13)
Mean ± SD
LF (n=7)
Mean ± SD p value
Cleaved caspase-3 1.2060.32 1.5660.61 0.2346
Active caspase-8 1.4660.92 1.0860.61 0.4758
Mitochondrial Bak 0.9960.52 0.8560.24 0.8741
Mitochondrial Bax 0.7060.36 0.8060.23 0.3417
Cytosolic cytochrome c 0.8660.41 1.0160.34 0.4281
Data are expressed in arbitrary optical density units.
doi:10.1371/journal.pone.0032829.t002
Figure3.Protein expressionlevelsofactivecaspase-8andcytosoliccytochromec accordingtothemedian ofpercent musclevolume.
The content of active caspase-8 (a) and cytosolic cytochrome c (b) was higher in participants with percent muscle volume below (median 2)
the median value of the study sample (48.6%) relative to those with percent muscle volume above the median (median +). AU: arbitrary units.
doi:10.1371/journal.pone.0032829.g003
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laboratory rodents [46,47]. Noteworthy, in our study sample,
mitochondrial Bax and Bak were among the variables describing
the regression model between apoptotic signaling proteins and GS
(Figure 2B). Furthermore, the regression coefficient of cytosolic
cytochrome c was close to the statistical significance. These
findings suggest that mitochondrial apoptotic signaling, and
potentially mitochondrial dysfunction, may contribute to decreas-
ing physical function at old age.
None of the apoptotic signaling pathways investigated correlat-
ed with either muscle strength or quality. Moreover, these
functional measures did not differ significantly between HF and
LF participants. Indeed, muscle strength was not correlated with
either the SPPB summary score or GS (data not shown). These
findings may be explained by the small sample size analyzed and
possibly by technical difficulties in achieving a true maximal peak
torque. Reasons underlying such limitation include a lack of
confidence of older persons with physical testing and apprehension
toward unfamiliar laboratory devices [48,49]. In addition, the
possibility exists that different levels of co-contraction could have
occurred in the two groups, thus influencing the strength testing
results. Finally, among PLS variables correlated with percent MV,
only active caspase-8 and cytosolic cytochrome c differed
significantly between participants with MV above or below the
median value of the study sample (Figure 3). In the case of GS,
none of the PLS significant variables differed between median
groups. Similarly, no differences in the apoptotic variables
describing PLS models were observed between functional groups.
While the discrepancy between PLS regressions and univariate
tests may be related to the small sample size analyzed, an
alternative explanation for this divergence can be proposed.
Indeed, the impact of apoptosis on functional and imaging
parameters is likely the result of the coordinated actions of multiple
apoptotic signaling proteins, rather than reflecting the effect of
individual mediators. In this scenario, multivariate analyses, such
as PLS regressions, may be better suited to capture the
information resulting from the interaction among multiple
signaling proteins.
In conclusion, findings from this study indicate that apoptotic
signaling in the skeletal muscle is correlated with percent MV and
GS in a cohort of relatively healthy, community-dwelling older
persons. Our data also suggest that specific signaling pathways of
apoptosis (i.e., mitochondrial caspase-dependent and death-
receptor pathways) are linked with measures of muscle mass and
physical function. These findings confirm previous observations in
animal models and suggest a novel biological target for
interventions against muscle aging and physical function decline.
Future larger-scale studies are needed to substantiate these
preliminary results and determine if down-regulation of apoptotic
signaling in skeletal myocytes via behavioral or pharmacological
interventions will provide improvements in the muscle mass and
functional status of older persons.
Limitations
Although reporting novel findings, the present work presents
some limitations that deserve further discussion. First, the study is
of exploratory nature, evident by the small sample size. This might
have hindered the detection of significant correlations between
apoptotic signaling proteins and muscle strength as well as the
observation of differences between functional and median groups
in the apoptotic variables describing PLS models. Moreover,
considering that skeletal myocyte apoptosis occurs throughout the
lifespan and supposedly accelerates in late life, only a ‘‘snapshot’’
of apoptotic signaling could be detected. Despite this limitation,
the present data show that a set of apoptotic signaling proteins
correlates with imaging and functional parameters, which makes
our findings highly relevant. It should also be considered that
recruiting LF older persons without severe comorbidity poses a
significant challenge, which adds further value to our results.
Circulating levels of inflammatory biomarkers associated with
physical performance (e.g., C-reactive protein, TNF-a, interleukin
6) were not measured. Therefore, correlations between inflamma-
tory markers and apoptotic signaling proteins could not be
explored. Although only subjects not engaged in regular exercise
were enrolled, the amount of physical activity of participants was
not quantified. Hence, the relationship between apoptotic
signaling and the overall level of physical activity could not be
established. In addition, due to its cross-sectional design, this study
does not allow to infer causality between apoptotic signaling and
measures of muscle mass and physical function. Future investiga-
tions will have to determine if the mitigation of apoptosis through
behavioral or pharmacological interventions results in ameliora-
tion of sarcopenia and physical performance. Finally, due to tissue
limitation, biochemical analyses were restricted to key components
of specific apoptotic pathways and the extent of DNA fragmen-
tation could not be assessed. However, the quantification of
cleaved caspase-3 expression is considered to be a reliable marker
of apoptosis [50].
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